Mercredi, 25 Novembre 2020
Dernières nouvelles
Principale » Short Interest in Exact Sciences Corporation (EXAS) Drops By 10.1%

Short Interest in Exact Sciences Corporation (EXAS) Drops By 10.1%

12 Juillet 2017

In other Exact Sciences Corporation news, SVP D Scott Coward sold 1,987 shares of Exact Sciences Corporation stock in a transaction dated Monday, July 3rd.

July 10, 2017Exact Sciences Corp. Its down 0.40, from 1.48 in 2016Q3. The company's stock had a trading volume of 754,821 shares.

While trading at volume below than average, Exact Sciences Corporation (NASDAQ:EXAS) previous 52-week high was $38.92 and moved up 203.52% over the same period, trading at a volume of 2.75 million. It has outperformed by 441.54% the S&P500.

Dividends is a reward scheme, that a company presents to its shareholders. Joseph Piotroski developed the F-Score which employs nine different variables based on the company financial statement. The company has market cap of $4.53 billion.

Since February 24, 2017, it had 0 insider buys, and 9 sales for $1.67 million activity. ARORA MANEESH sold $238,968 worth of stock. LIDGARD GRAHAM PETER had sold 2,945 shares worth $62,316. The FCF Growth of Exact Sciences Corporation (NasdaqCM:EXAS) is 1.000000. Therefore 57% are positive. At recent closing price of $37.93, EXAS has a chance to add $1.15 or 3.03% in 52 weeks, based on mean target price ($39.08) placed by analysts.The analyst consensus opinion of 1.8 looks like a buy. The rating was initiated by BTIG Research with "Buy" on Friday, December 18. The firm earned "Buy" rating on Wednesday, May 31 by Canaccord Genuity. Mizuho maintained the shares of EXAS in report on Wednesday, October 7 with "Buy" rating. Metropolitan Life Insur has invested 0.01% of its portfolio in EXACT Sciences Corporation (NASDAQ:EXAS).

Investors sentiment decreased to 0.29 in Q4 2016. It worsened, as 35 investors sold EXAS shares while 56 reduced holdings. 31 funds opened positions while 67 raised stakes. (NASDAQ:ZNGA) has been 13.47 million shares per day over the past 30 days. Botty Investors LLC purchased a new stake in Exact Sciences Corporation during the first quarter valued at $200,000. Raymond James invested in 111,809 shares.

Customs seized five cobras found at NYC mail facility from China
The contents of one package were described as a "plastic tray", but an x-ray showed the contents were snakes in a round container. It's not exactly snakes on a plane, but USA customs agents got a slithery surprise at JFK International Airport.

Exact Sciences Cor (NASDAQ:EXAS) now has a trailing P/E of -25.29 while its forward P/E according to Thomson Reuters is -41.14. American Bancshares holds 0.11% or 5,765 shares. Deerfield Management stated it has 0.27% of its portfolio in EXACT Sciences Corporation (NASDAQ:EXAS).

Exact Sciences Corporation (NASDAQ:EXAS)'s latest quote $37.03 $0.1 2.8% will find technical support in $36.21 a share and a breakdown below this region would be a significantly bearish signal for Exact Sciences Corporation traders. Finally, Ameritas Investment Partners Inc. raised its position in Exact Sciences Corporation by 455.0% in the first quarter. Teton Advsr holds 20,000 shares or 0.01% of its portfolio.

10,700 are owned by Gofen Glossberg Ltd Il. Exact Sciences Corporation had a negative net margin of 116.39% and a negative return on equity of 49.24%.

Vetr lowered shares of Exact Sciences Corporation (NASDAQ:EXAS) from a buy rating to a hold rating in a research note released on Thursday morning. Whereas, in last 21 trading days (one month) was climbed 6.60% and surged in last 63 trading days (quarter) of 63.67%. The medical research company reported ($0.32) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.41) by $0.09.

Whereas they predicted High and Low Earnings Estimate as $-0.27 and $-0.39 respectively. KEY's profit will be $373.98 million for 14.20 P/E if the $0.34 EPS becomes a reality. During the same period in the prior year, the firm earned ($0.49) earnings per share. (NYSE:MRK) rating on Thursday, August 27. They now have a Dollars 15 price target on the stock. Meanwhile, due to an ongoing pressure which caused a decline of nearly -5.75% in the past five days, the stock price is now down -35.56% so far on the year - still in weak territory. The rating was maintained by Jefferies with "Buy" on Tuesday, July 4. The firm has "Sector Underperform" rating by Scotia Capital given on Thursday, January 5. As per Tuesday, November 8, the company rating was downgraded by Citigroup. This will give analytical advantage to a shorter-term trader since it pursues the price more intimately, and consequently produces less "lag" as comparison to the longer-term moving average. (NYSE:MRK) has risen 16.86% since July 11, 2016 and is uptrending.

Total cash per share on the most recent quarter is 2.47. Citadel Advsrs Ltd Company invested in 0% or 198,774 shares. The lower the Q.i. value, the more undervalued the company is thought to be. New York-based Cohen Steers has invested 0% in Merck & Co., Inc.